Medinno Pharmaceutical Technology

Medinno Pharmaceutical Technology is a clinical-stage biotechnology company focused on developing innovative, locally administered small-molecule therapeutics for dermatological, ophthalmic, and chronic wound healing indications. The company's lead candidate, MDI-1228, is a first-in-class topical pan-JAK/pan-Trk inhibitor designed with a unique pharmacokinetic profile that achieves high local tissue concentration with zero systemic exposure, thereby avoiding the systemic side effects typical of traditional JAK inhibitors. MDI-1228 is currently in Phase II clinical trials for diabetic foot ulcers and has completed Phase I trials for allergic conjunctivitis, with additional IND approvals for atopic dermatitis, psoriasis, and seasonal allergic rhinitis. Headquartered in Xiamen, China, with R&D centers in Shanghai and Zhuhai, Medinno aims to build a highly differentiated pipeline addressing massive global patient populations with significant unmet medical needs.